Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Cash & Current Investments (2018 - 2025)

Historic Cash & Current Investments for Dna X (SONM) over the last 8 years, with Q3 2025 value amounting to $4.3 million.

  • Dna X's Cash & Current Investments fell 5228.48% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year decrease of 5228.48%. This contributed to the annual value of $8.0 million for FY2024, which is 1619.76% down from last year.
  • Dna X's Cash & Current Investments amounted to $4.3 million in Q3 2025, which was down 5228.48% from $5.4 million recorded in Q2 2025.
  • In the past 5 years, Dna X's Cash & Current Investments registered a high of $18.2 million during Q2 2022, and its lowest value of $4.3 million during Q3 2025.
  • In the last 5 years, Dna X's Cash & Current Investments had a median value of $9.6 million in 2024 and averaged $10.0 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first crashed by 8188.22% in 2021, then soared by 16326.86% in 2022.
  • Over the past 5 years, Dna X's Cash & Current Investments (Quarter) stood at $12.3 million in 2021, then increased by 7.65% to $13.2 million in 2022, then decreased by 27.39% to $9.6 million in 2023, then fell by 16.2% to $8.0 million in 2024, then tumbled by 46.23% to $4.3 million in 2025.
  • Its Cash & Current Investments stands at $4.3 million for Q3 2025, versus $5.4 million for Q2 2025 and $4.9 million for Q1 2025.